Baseline characteristics

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma · Source last updated 2015-02-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      34

   units

   Participants

groups

1. description

   Patients receive oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.

   id

   BG000

   title

   Arm I

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            49

            upper Limit

            84

            value

            73

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            6

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            28

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            34

      title

      United States

   param Type

   NUMBER

   title

   Region of Enrollment

   unit Of Measure

   participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice